Lumos Pharma (LUMO)
(Delayed Data from NSDQ)
$2.81 USD
-0.02 (-0.71%)
Updated Apr 30, 2024 03:57 PM ET
After-Market: $2.87 +0.06 (2.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LUMO 2.81 -0.02(-0.71%)
Will LUMO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LUMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LUMO
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
LUMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lumos Pharma (LUMO) Reports Q3 Loss, Lags Revenue Estimates
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top Estimates
Other News for LUMO
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
Lumos Pharma’s LUM-201 Receives ‘Buy’ Rating on Strong Market Position and Promising Trial Outcomes
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
Lumos Pharma receives notice of allowance from USPTO for LUM-201 patent
Analysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)